Three Seasons Wealth LLC Invests $604,000 in Pacira BioSciences, Inc. $PCRX

Three Seasons Wealth LLC bought a new position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 23,331 shares of the company’s stock, valued at approximately $604,000.

Other institutional investors also recently bought and sold shares of the company. Hantz Financial Services Inc. increased its holdings in Pacira BioSciences by 175.4% in the 3rd quarter. Hantz Financial Services Inc. now owns 1,132 shares of the company’s stock valued at $29,000 after acquiring an additional 721 shares during the last quarter. Tidemark LLC bought a new position in shares of Pacira BioSciences during the 3rd quarter valued at about $56,000. Strs Ohio purchased a new position in shares of Pacira BioSciences during the first quarter valued at about $75,000. iSAM Funds UK Ltd purchased a new position in shares of Pacira BioSciences during the third quarter valued at about $80,000. Finally, Vestcor Inc bought a new stake in shares of Pacira BioSciences in the third quarter worth about $90,000. 99.73% of the stock is owned by hedge funds and other institutional investors.

Pacira BioSciences Stock Performance

Pacira BioSciences stock opened at $22.60 on Wednesday. The company’s 50-day moving average price is $22.02 and its 200-day moving average price is $23.29. The company has a quick ratio of 3.28, a current ratio of 4.54 and a debt-to-equity ratio of 0.54. The company has a market cap of $915.07 million, a PE ratio of 150.67 and a beta of 0.21. Pacira BioSciences, Inc. has a twelve month low of $18.80 and a twelve month high of $27.64.

Pacira BioSciences (NASDAQ:PCRX) last announced its quarterly earnings results on Thursday, February 26th. The company reported $0.57 EPS for the quarter, missing analysts’ consensus estimates of $0.85 by ($0.28). The business had revenue of $196.87 million during the quarter, compared to the consensus estimate of $201.93 million. Pacira BioSciences had a net margin of 0.97% and a return on equity of 10.39%. The firm’s revenue was up 5.1% on a year-over-year basis. During the same period in the previous year, the business posted $0.91 EPS. On average, equities research analysts forecast that Pacira BioSciences, Inc. will post 2.41 EPS for the current fiscal year.

Insider Buying and Selling

In other news, SVP Lauren Riker sold 4,000 shares of the business’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $20.81, for a total transaction of $83,240.00. Following the transaction, the senior vice president owned 52,313 shares of the company’s stock, valued at approximately $1,088,633.53. The trade was a 7.10% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Jonathan Slonin sold 3,261 shares of the business’s stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $22.82, for a total value of $74,416.02. Following the transaction, the insider directly owned 223,640 shares in the company, valued at approximately $5,103,464.80. This represents a 1.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 8,677 shares of company stock worth $191,980. Company insiders own 6.40% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on PCRX. HC Wainwright reiterated a “buy” rating and issued a $38.00 target price on shares of Pacira BioSciences in a research report on Friday, January 9th. Wall Street Zen cut Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 28th. Barclays reduced their price objective on Pacira BioSciences from $27.00 to $25.00 and set an “equal weight” rating on the stock in a research note on Thursday, March 26th. Zacks Research downgraded Pacira BioSciences from a “hold” rating to a “strong sell” rating in a research report on Monday, March 9th. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Pacira BioSciences in a research report on Monday, December 29th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Pacira BioSciences has an average rating of “Hold” and a consensus target price of $30.25.

Pacira BioSciences Profile

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.